Endometrial cancer begins in the lining of the uterus (endometrium) and is the most common gynecologic malignancy. Most cases are diagnosed at an early stage due to abnormal uterine bleeding, and early detection leads to excellent cure rates.
Globally, endometrial cancer is the sixth most common cancer in women, with over 420,000 new cases diagnosed annually. While often found early, timely intervention remains essential to achieve the best outcomes — so prompt medical evaluation at the first sign of symptoms is critical.
China sees approximately 70,000 new cases of endometrial cancer each year, accounting for nearly 17% of the global burden. At Fosun Health, this substantial case volume gives our expert teams a depth of experience that ensures precision in every aspect of care — from accurate molecular classification and minimally invasive surgery to individualized adjuvant therapy and long term survivorship management.
Every endometrial cancer program has surgery, radiation, and hormones. Here is what makes ours different:
"I am only 32 and have never had children. Can you treat the cancer without taking my uterus?"
The challenge: Endometrial cancer is increasingly diagnosed in women under 40 who have not completed their families. The traditional answer is total hysterectomy and bilateral salpingo-oophorectomy—curing the cancer but ending fertility forever. For a young woman, this can feel like trading one life for another.
Our answer: Fertility-sparing management for carefully selected young patients with early-stage, low-grade disease:
- High-Dose Oral Progestin Therapy: For Stage IA, Grade 1 endometrioid adenocarcinoma in patients wishing to preserve fertility. We prescribe medroxyprogesterone acetate (MPA) or megestrol acetate at high doses for 6–9 months, with serial hysteroscopic evaluation every 3 months to monitor response. Complete pathological regression is achieved in 60–80% of carefully selected patients.
- Hysteroscopic Tumor Resection + Progestin: Combining hysteroscopic resection of the visible tumor with adjuvant high-dose progestin therapy may improve response rates over progestin alone.
- Rigorous Follow-Up Protocol: After achieving complete response, we guide patients through assisted reproduction and closely monitored early pregnancy—with planned definitive surgery (hysterectomy) after childbearing is complete.
- Robotic Precision for Conservative Surgery: When fertility preservation is not appropriate but maximal uterine preservation is, robotic-assisted focal resection with sentinel lymph node mapping ensures oncological safety with minimal tissue loss.
What this means for you: Being diagnosed with endometrial cancer in your 30s does not automatically mean you will never carry a pregnancy. With strict selection, hormonal therapy, and meticulous monitoring, you can treat the cancer—and still become a mother.
"They told me my cancer is MSI-High. What does that mean? And does it give me better options?"
The challenge: Endometrial cancer has one of the highest rates of MSI-H/dMMR (microsatellite instability / deficient mismatch repair) of any solid tumor—approximately 25–30%. These tumors are inherently "immunogenic," meaning they trigger a strong immune response that can be unleashed with checkpoint inhibitors. Yet in many regions, immunotherapy is reserved for late-stage disease or remains unavailable.
Our answer: We leverage molecular classification from day one to match your tumor biology to the most effective systemic therapy:
- MSI-H/dMMR Endometrial Cancer: For advanced or recurrent disease, pembrolizumab (anti-PD-1) is approved in China and delivers deep, durable responses in a substantial proportion of patients. This is not incremental improvement—it can be transformational.
- POLE-Ultramutated: Ultra-hypermutated tumors with an extraordinary number of neoantigens. These have an intrinsically excellent prognosis and may be candidates for de-escalated therapy or immunotherapy in select settings.
- p53-Mutated: More aggressive, resembling ovarian serous carcinoma. We treat these with platinum-based chemotherapy + anti-angiogenic therapy, similar to ovarian cancer protocols.
- CTNNB1-Mutated: Associated with resistance to standard hormonal therapy; we adjust systemic treatment accordingly.
- China-Original Protocols & Cost: Domestic PD-1/PD-L1 inhibitors combined with chemotherapy or targeted agents are in routine use here, often years ahead of availability elsewhere. Comprehensive treatment costs are 30%–50% of what you would pay in Europe or the US—with zero compromise in quality.
Guided by NGS-based molecular classification (TCGA/ProMisE) and physicians who have managed hundreds of molecularly complex endometrial cancer cases.
What this means for you: Your tumor's molecular class—MSI-H, POLE-mutated, p53-abnormal, or CTNNB1-mutated—determines the optimal therapy from the outset. And if you are MSI-H, immunotherapy offers a genuine chance at long-term disease control that chemotherapy alone cannot provide.
"My cancer has returned at the vaginal cuff or in the pelvic lymph nodes after my initial surgery. Do I need another major operation?"
The challenge: Local recurrence after initial hysterectomy—at the vaginal cuff, in pelvic sidewall lymph nodes, or within the pelvic cavity—is a devastating event. Many patients are told that repeat extensive pelvic surgery is their only option, with significant risks of bladder and bowel injury. Others are deemed inoperable and referred for palliative care alone.
Our answer: CyberKnife M6 and Iodine-125 seed implantation provide curative-intent salvage without removing a single additional organ:
- CyberKnife M6: For isolated vaginal cuff recurrences or pelvic lymph node relapses, 0.1mm sub-millimeter stereotactic radiosurgery tracks tumor motion in real time and converges radiation from thousands of angles. It ablates the recurrence while maximally sparing the bladder, rectum, and small bowel. 1–5 outpatient sessions. No incision. No organ removal. No interruption to systemic therapy.
- Iodine-125 Seed Implantation: For bulky pelvic recurrences or para-aortic lymph node disease, rice-grain-sized radioactive seeds are implanted directly into the tumor under image guidance. They emit continuous internal radiation for 60–180 days—hitting the cancer from the inside out while surrounding organs receive minimal exposure.
- Interventional Arterial Therapy: For recurrence with significant bleeding, superselective transarterial infusion delivers drug concentrations 50–100× higher than IV therapy directly to tumor-feeding branches—shrinking the mass and controlling hemorrhage.
What this means for you: Recurrence after initial surgery does not automatically mean another major pelvic operation. Depending on the pattern, we can precision-radiate it, seed it with internal radiation, or starve it through targeted arterial therapy—while your remaining pelvic organs remain untouched.
"If I need a hysterectomy, how big will the incision be? How long until I can walk, eat, and start chemotherapy?"
The challenge: Traditional open hysterectomy for endometrial cancer requires a large midline abdominal incision, extended hospitalization, and 6–8 weeks of recovery before chemotherapy can begin. For a disease where timely adjuvant therapy directly impacts survival, delays are dangerous. The trauma of open surgery also increases the risk of complications in an increasingly obese patient population.
Our answer: Robotic-assisted minimally invasive surgery as the default approach:
- Robotic Total Hysterectomy + BSO + Staging: The Da Vinci robot provides 10× magnified 3D vision and tremor-free wristed instruments that perform precise extrafascial hysterectomy, bilateral salpingo-oophorectomy, pelvic and para-aortic lymphadenectomy, and omental biopsy through 4–5 small incisions. Sub-millimeter precision minimizes blood loss, reduces wound complications, and accelerates recovery.
- Sentinel Lymph Node Mapping: Using ICG (indocyanine green) fluorescence, we identify and biopsy the first-draining lymph nodes—avoiding complete lymphadenectomy in low-risk patients and reducing lymphedema and lower extremity swelling risk.
- ERAS Protocol: Enhanced Recovery After Surgery protocols ensure early mobilization, early feeding, and early discharge—allowing adjuvant chemotherapy to begin within 2–3 weeks rather than 6–8 weeks.
What this means for you: Your hysterectomy and staging surgery can be performed through keyhole incisions with minimal pain, rapid recovery, and a faster return to normal life—and to the chemotherapy that will protect you from recurrence.
When standard therapies reach their limit, we provide rapid access to China's full portfolio of Phase III clinical trials—therapies typically 3–5 years ahead of availability elsewhere. NGS-based molecular matching identifies trials targeting your specific mutation (POLE, MSI, p53, Lynch). Every enrollment is ethics-approved with full medical supervision.
Our TCM program runs alongside your primary treatment as a "hormonal balance and vitality optimizer":
Toxicity Reduction: Herbal formulations help protect bone marrow function, ease chemotherapy-induced nausea and vomiting, reduce cancer-related fatigue, and mitigate peripheral neuropathy. Specialized protocols address hormonal changes after oophorectomy—hot flashes, mood changes, and bone density protection.
Efficacy Enhancement: Selected preparations may improve tumor sensitivity to chemotherapy or hormonal agents.
Acupuncture provides additional support for pain, nausea, fatigue, and postoperative bladder/bowel dysfunction. The goal: smooth your recovery, protect your hormonal equilibrium, and keep you strong enough to complete every planned treatment cycle.
Every endometrial cancer case is reviewed by a panel comprising gynecologic oncology surgery, medical oncology, radiation oncology, reproductive endocrinology (for fertility preservation), interventional radiology, radiology, pathology, and genetic counseling specialists. Endometrial cancer decisions are uniquely complex: fertility preservation versus immediate hysterectomy; molecular classification guiding systemic therapy selection; and management of Lynch syndrome-associated hereditary risk.
The MDT convenes within 48 hours of complete documentation. Your plan is a consensus decision optimized for your cancer stage, molecular class, fertility desires, genetic risk, and your priorities.
Diagnosis:
Stage I Endometrioid Adenocarcinoma of the Endometrium
Treatment Plan:
Da Vinci robot-assisted total hysterectomy with bilateral salpingo-oophorectomy and sentinel lymph node mapping. The procedure was completed uneventfully with satisfactory postoperative recovery. Intraoperatively, lymphovascular invasion was identified. After discussion with the patient, adjuvant CyberKnife-based vaginal cuff brachytherapy was administered.
Outcome:
At the one-year follow-up, no pelvic recurrence was detected. PET/CT showed no evidence of metastatic disease. The patient remained fully independent in daily activities and had resumed a normal retirement lifestyle, including travel and volunteer work.
Led by Dr. Yang Jun, Prof. Luo Pengfei, and Prof. Chen Tao, the Fosun Oncology Center brings together more than 20 world-class medical experts, each with over a decade of extensive oncology experience. Supported by a comprehensive range of advanced therapies — including robotic surgery, precision radiotherapy, minimally invasive intervention, CAR-T cell therapy, and Tumor Treating Fields (TTFields) — the center delivers one-stop, integrated cancer care designed to make treatment more accessible, efficient, and high-quality for every patient.
Key Highlights
- Over 60,000 annual oncology patient admissions across Fosun’s major international hospitals in 2025
More than 17,000 cumulative TACE procedures completed between 2023 and 2025 at Fosun Hospital Guangzhou alone, with international patients accounting for over 10% of total cases
- More than 1,000 successful CyberKnife treatments performed, demonstrating world-class expertise in precision radiotherapy
- A 29.3% five-year survival rate achieved for Glioblastoma Multiforme (GBM) through combined TTFields therapy, representing a significant improvement over the 4.7% baseline
Core Services
- Robotic surgery
- Precision radiotherapy
- Minimally invasive intervention
- CAR-T cell therapy
- Tumor Treating Fields (TTFields)
- Medical oncology
- PET/CT imaging
- Pulmonary nodule diagnosis
- VIP inpatient wards
- Integrated oncology clinics
- Traditional Chinese medicine for oncology
- Cancer screening and early detection
- Genetic testing and counseling
Founded in 1992, Fosun has grown over the past three decades into a global innovation-driven consumer group. In 2007, Fosun International Limited was listed on the Main Board of the Hong Kong Stock Exchange (stock code: 00656.HK). As one of the few Chinese enterprises with strong global operational and investment capabilities, Fosun has developed substantial technological expertise and innovation capacity across multiple industries.
Established in 2010, Shanghai Fosun Health Technology is dedicated to building a world-renowned healthcare group in Asia. Today, the group operates 19 affiliated medical institutions across Foshan, Guangzhou, Shenzhen, Zhuhai, Shanghai, and other major cities, with a total of 6,600 hospital beds and 9 Internet Hospital licenses. Fosun Health ranks No. 1 among China’s private comprehensive medical groups. Its flagship institution, Fosun Foshan Chancheng Hospital, has ranked first among private hospitals in China for eight consecutive years and was honored with the 2026 Global Health Asia-Pacific “Oncological Medical Service Provider of the Year” award.
As the flagship hospital of Fosun Health, Fosun Foshan Chancheng Hospital was founded in 1958. The hospital currently hosts 28 key specialty development programs, including 2 provincial-level, 13 municipal-level, and 13 district-level key specialties. Its services span 22 medical disciplines, including spinal orthopedics, traditional Chinese medicine gynecology, obstetrics and gynecology, cardiovascular medicine, clinical laboratory medicine, anesthesiology, pediatrics, critical care medicine, ultrasound medicine, rehabilitation medicine, general practice, general surgery, and urology.
The hospital is equipped with globally advanced medical technologies, including the CyberKnife system and the Da Vinci Surgical Robot. It has 1,750 approved hospital beds and a multidisciplinary team of more than 2,800 medical professionals. The hospital records nearly 3.19 million outpatient visits annually and more than 67,000 inpatient discharges each year.
Fosun Foshan Chancheng Hospital has received numerous prestigious recognitions, including:
Global Health Asia-Pacific “Traditional Chinese Medicine Hospital of the Year”
Global Health China “Hospital of the Year”
No. 1 ranking on the GAHA Top 500 Private Hospitals in China list for eight consecutive years
The hospital has also been recognized as:
A National Model Unit for Improved Medical Services
A National Drug Clinical Trial Institution (GCP)
A National Standardized Residency Training Base
Established in 2003, Guangzhou Fosun Chancheng Hospital specializes in cardiovascular medicine, oncology, and neurosciences. The hospital has established a National Chest Pain Center, Stroke Center, Trauma Center, and MDT Center, supporting the development of emergency medicine, obstetrics and gynecology, intensive care, anesthesiology, gastroenterology, general surgery, urology, and general practice.
The hospital operates more than 800 inpatient beds and 48 clinical and medical technology departments, supported by a team of over 880 healthcare professionals.
Guangzhou Fosun Chancheng Hospital has received several honors and industry recognitions, including:
EMBA Innovation Practice Base
Guangdong Private Medical Reform & Innovation Brand
Guangdong Private Medical Industry Pioneer Brand
Outstanding Brand Hospital for Medical Investment Contribution
Upload your transvaginal ultrasound images, MRI/CT scans, endometrial biopsy/pathology report, and NGS results (molecular subtype, MSI, HER2). Our multidisciplinary endometrial cancer team will provide a personalized treatment plan—including fertility preservation assessment and interventional downstaging strategy—within 48 hours.
